Kupando raises €10M more to take its immunity drug into the clinic
By Ana-Maria Stanciuc
Published on March 18, 2026.
Kupando has raised €10 million in Series A financing to bring total funding to €23 million for its dual TLR agonist KUP101, a drug that targets solid tumours and drug-resistant infections. The funding was led by Remiges Ventures, the Seattle and Tokyo-based cross-border VC firm, and co-led by LifeCare Partners. Additional investors included Brandenburg Kapital, High-Tech Gründerfonds, and Ventura Biomed Investors. Kupando was founded in 2018 by Johanna Holldack, a physician and serial biotech executive. KUPando's approach is tissue-agnostic, not designed for a specific tumour type, broadening its potential patient population.
Related Articles
US wholesale prices spiked in February, reflecting pre-Iran war inflation pressures
US wholesale inflation surged to 0.7% in February due to higher food and service costs, despite a slight slowdown in consumer sentiment.
Medicare open enrollment has a Medigap trap most people miss
Despite guaranteed Medigap coverage, many retirees miss key eligibility window windows for Medicare Advantage plans, leaving behind potentially costly, unpredictable, and unpredictable health care options.
Bank of Montreal ‘cautiously optimistic’ on Texas as D-FW economy stays firm
Bank of Montreal is cautiously optimistic about Texas’s economic prospects, citing strategic investment and strong talent, despite recent job creation challenges.